ThinkSabio

$BBIO

$65.35▲ +0.5% YTD

15 SEC 13D/G filings tracked · Last updated Oct 11, 2026

Filing History
News
BBIO ▲ +0.5% - BridgeBio Pharma, Inc.
CP $65.35▲ +0.5%Oct 11, 2026 · ThinkSabio Blog

$BBIO - Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. El…

News
BBIO ▲ +0.5% - BridgeBio Pharma, Inc.
CP $65.35▲ +0.5%Oct 11, 2026 · ThinkSabio Blog

$BBIO - Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1…

News
BBIO ▲ +2.0% - BridgeBio Pharma, Inc.
CP $67.44▲ +2.0%Oct 6, 2026 · ThinkSabio Blog

$BBIO - BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting…

News
BBIO ▲ +2.0% - BridgeBio Pharma, Inc.
CP $67.44▲ +2.0%Oct 6, 2026 · ThinkSabio Blog

$BBIO - BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026…

News
BBIO ▲ +0.9% - BridgeBio Pharma, Inc.
CP $66.76▲ +0.9%Oct 6, 2026 · ThinkSabio Blog

$BBIO - BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day…

News
BBIO ▲ +1.3% - BridgeBio Pharma, Inc.
CP $66.99▲ +1.3%Oct 6, 2026 · ThinkSabio Blog

$BBIO - BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia…

News
BBIO ▼ -1.5% - BridgeBio Pharma, Inc.
CP $66.14▲ -1.5%Oct 5, 2026 · ThinkSabio Blog

$BBIO - BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day…

News
BBIO ▲ +1.2% - BridgeBio Pharma, Inc.
CP $67.98▲ +1.2%Oct 5, 2026 · ThinkSabio Blog

$BBIO - BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels…

News
BBIO ▲ +0.4% - BridgeBio Pharma, Inc.
CP $69.50▲ +0.4%Sep 23, 2026 · ThinkSabio Blog

$BBIO - Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening…

News
BBIO ▼ -0.1% - BridgeBio Pharma, Inc.
CP $74.76▲ -0.1%Sep 9, 2026 · ThinkSabio Blog

$BBIO - Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial…

News
BBIO ▼ -2.5% - BridgeBio Pharma, Inc.
CP $76.69▲ -2.5%Aug 30, 2026 · ThinkSabio Blog

$BBIO - Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and F…

SEC 13D/G
BBIO - BridgeBio Pharma, Inc. - SEC Filing Update (17-AUG-2026) | ThinkSabio - Stocks Simplified
$80.00▲ 2.25%Aug 17, 2026 · ThinkSabio Blog

$BBIO SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #BBIO BridgeBio Pharma, Inc. : $80.00 Sector: Healthcare | YTD:…

SEC 13D/G
$BBIO SEC Filing Update (03-AUG-2026) | ThinkSabio - Stocks Simplified
$80.09▲ 2.36%Aug 3, 2026 · ThinkSabio Blog

$BBIO SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #BBIO : $80.09 Sector: Healthcare | YTD: 🔼+ 2.36% The SEC disclo…

SEC 13D/G
$BBIO SEC Filing Update (27-JUL-2026) | ThinkSabio - Stocks Simplified
$84.20▲ 7.62%Jul 27, 2026 · ThinkSabio Blog

$BBIO SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #BBIO : $84.20 Sector: Healthcare | YTD: 🔼+ 7.62% The SEC disclo…

SEC 13D/G
$BBIO SEC Filing Update (10-JUL-2026) | ThinkSabio - Stocks Simplified
$85.89▲ 9.78%Jul 10, 2026 · ThinkSabio Blog

$BBIO SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #BBIO : $85.89 Sector: Healthcare | YTD: 🔼+ 9.78% The SEC disclo…